Radioligand Therapy Market Size, Share & Trends Analysis Report By Isotope (Lutetium-177 (Lu-177), Actinium-225 (Ac-225), Iodine-131 (I-131), Other Isotopes), By Target (Prostate-Specific Membrane Antigen, Ki 67 Expression and Grading, Cytochrome P450 17A1 Inhibitor), By Indication (Prostate Cancer, Neuroendocrine Tumours (NETs), Others), By End-User (Hospitals, Ambulatory Surgical Centers, Cancer Treatment Centers, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034